Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

STS-01

Generic Name: STS-01

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)

Phase 2

Completed

Posted: 2024/05/07

Sponsor:

Soterios Ltd

ID:NCT06402630

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

FDA Rejects Satsuma's STS101 Nasal Migraine Treatment Citing Manufacturing Issues

5 months ago

The FDA issued a complete response letter for Satsuma Pharmaceuticals' STS101, a nasal powder formulation of dihydroergotamine mesylate (DHE), due to chemistry, manufacturing, and controls (CMC) issues.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy